Cartesian Therapeutics (RNAC) PT Raised to $43 at Canaccord Genuity
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Price: $9.18 --0%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Join SI Premium – FREE
Canaccord Genuity analyst John Newman raised the price target on Cartesian Therapeutics (NASDAQ: RNAC) to $43.00 (from $38.00) while maintaining a Buy rating.
You May Also Be Interested In
- Ollie's Bargain Outlet (OLLI) PT Lowered to $113 at Piper Sandler, 'Favorable Risk/Reward for 2H '
- National Australia Bank Ltd. (NAB:AU) (NABZY) PT Lowered to AUD48.50 at UBS
- Aurizon Holdings (AZJ:AU) (QRNNF) PT Lowered to AUD3.40 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
